New cancer drug EXS74539 enters first human trials

NCT ID NCT07517198

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any signs that the drug is shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EXS74539 (REC-4539), an oral drug
What this could lead to: If successful, this could lead to a new treatment option for several types of solid tumors.
What could go wrong: This is an early Phase 1 trial with only 40 participants, focused on safety and dosing. It is too early to know if the drug will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of liver and intrahepatic biliary tract gastric cancer gastric neoplasm head and neck squamous cell carcinoma liver cancer Liver Neoplasms Margins of Excision neuroendocrine carcinoma non-small cell lung carcinoma ovarian cancer prostate cancer renal carcinoma renal cell carcinoma small cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HEPATIC CANCER HIGH GRADE NEUROENDOCRINE CANCER NON-SMALL CELL LUNG CANCER (NSCLC) OVARIAN CANCER PROSTATE CANCER RENAL CARCINOMA (CLEAR AND NON-CLEAR CELL) SMALL CELL CARCINOMAS OF NON-LUNG ORIGIN SMALL CELL LUNG CANCER ( SCLC ) SOLID TUMOR TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

START Dallas
RECRUITING

Fort Worth, Texas, 76104, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
Start Lacn
RECRUITING

Los Angeles, California, 90025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.